Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib
Executive Summary
With many on the executive team who worked on the drug previously, Sierra thinks the stalled Phase III compound could be differentiated from Jakafi and others in the myelofibrosis space based on anemia benefit.
You may also be interested in...
Another New Home For Momelotinib As GSK Buys Sierra
GlaxoSmithKline is paying a 39% premium to buy Sierra Oncology and its myelofibrosis therapy momelotinib which is set to be filed shortly in the US on the back of a strong Phase III package.
Sierra Sees Momelotinib ‘Sweet Spot’ In Anemic Myelofibrosis Population
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.